Growth Metrics

Insight Molecular Diagnostics (IMDX) Current Assets (2020 - 2025)

Insight Molecular Diagnostics' Current Assets history spans 6 years, with the latest figure at $21.4 million for Q3 2025.

  • For Q3 2025, Current Assets rose 346.25% year-over-year to $21.4 million; the TTM value through Sep 2025 reached $21.4 million, up 346.25%, while the annual FY2024 figure was $11.8 million, 9.92% up from the prior year.
  • Current Assets for Q3 2025 was $21.4 million at Insight Molecular Diagnostics, down from $26.8 million in the prior quarter.
  • Across five years, Current Assets topped out at $62.8 million in Q1 2021 and bottomed at $4.8 million in Q3 2024.
  • The 5-year median for Current Assets is $24.6 million (2022), against an average of $27.2 million.
  • The largest annual shift saw Current Assets plummeted 71.67% in 2024 before it skyrocketed 454.9% in 2025.
  • A 5-year view of Current Assets shows it stood at $39.1 million in 2021, then tumbled by 34.76% to $25.5 million in 2022, then crashed by 58.11% to $10.7 million in 2023, then rose by 9.92% to $11.8 million in 2024, then surged by 81.89% to $21.4 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Current Assets are $21.4 million (Q3 2025), $26.8 million (Q2 2025), and $36.3 million (Q1 2025).